SMMT
Summit TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The April 30 company update kept the core ivonescimab timeline intact: ASCO OS data on May 31, HARMONi-3 squamous final PFS still in 2H 2026, and the November 14, 2026 PDUFA unchanged. The interim HARMONi-3 review did not raise safety concerns, which preserves the lead-program thesis [#8-K-2026-04-30].
Posture
Defensive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-06-03.
What can break
Lead-asset concentration remains extreme; ivonescimab drives the thesis, so weak ASCO, Phase III, or FDA outcomes could re-rate the equity sharply lower.
Momentum
11
Value
41
Sentiment
58
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $15.00 · Bull $24.00 · Bear $9.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $31.71
Why
Momentum11 · Δ7d +1.0
Value41 · Δ7d +0.1
Sentiment58 · Δ7d +8.9
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
11
34% active weight
Current posture
7d trendImproving
Δ7d
+1.0
Δ21d
-56.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
58
33% active weight
Current posture
7d trendImproving
Δ7d
+8.9
Δ21d
+24.0
Why this grade
Composite grade F. Momentum 11.2 / Value 41.1 / Sentiment 58.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$11.53B
Beta
-1.44
Shares Out
744.44M
P/E (TTM) · Derived
-10.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-42.46
Rev YoY
-
EPS YoY
-302.8%
Gross Margin
-
Op Margin
-
Net Debt
-$412.35M
Current Ratio
3.80
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology